PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.